全文获取类型
收费全文 | 428268篇 |
免费 | 36857篇 |
国内免费 | 12449篇 |
专业分类
耳鼻咽喉 | 4444篇 |
儿科学 | 8140篇 |
妇产科学 | 6101篇 |
基础医学 | 48388篇 |
口腔科学 | 12040篇 |
临床医学 | 34062篇 |
内科学 | 54773篇 |
皮肤病学 | 6762篇 |
神经病学 | 30023篇 |
特种医学 | 11063篇 |
外国民族医学 | 48篇 |
外科学 | 36276篇 |
综合类 | 59549篇 |
现状与发展 | 31篇 |
一般理论 | 24篇 |
预防医学 | 40985篇 |
眼科学 | 4443篇 |
药学 | 57822篇 |
393篇 | |
中国医学 | 38112篇 |
肿瘤学 | 24095篇 |
出版年
2024年 | 1590篇 |
2023年 | 8133篇 |
2022年 | 16163篇 |
2021年 | 20159篇 |
2020年 | 18379篇 |
2019年 | 19329篇 |
2018年 | 17809篇 |
2017年 | 16358篇 |
2016年 | 15226篇 |
2015年 | 15449篇 |
2014年 | 27241篇 |
2013年 | 28546篇 |
2012年 | 24422篇 |
2011年 | 27194篇 |
2010年 | 21673篇 |
2009年 | 20173篇 |
2008年 | 19582篇 |
2007年 | 18776篇 |
2006年 | 16212篇 |
2005年 | 14211篇 |
2004年 | 12077篇 |
2003年 | 10565篇 |
2002年 | 8377篇 |
2001年 | 6982篇 |
2000年 | 6199篇 |
1999年 | 5363篇 |
1998年 | 4665篇 |
1997年 | 4378篇 |
1996年 | 3908篇 |
1995年 | 3655篇 |
1994年 | 3316篇 |
1993年 | 2904篇 |
1992年 | 2583篇 |
1991年 | 2323篇 |
1990年 | 2086篇 |
1989年 | 1907篇 |
1988年 | 1797篇 |
1987年 | 1610篇 |
1986年 | 1679篇 |
1985年 | 3446篇 |
1984年 | 3619篇 |
1983年 | 2493篇 |
1982年 | 2939篇 |
1981年 | 2290篇 |
1980年 | 2013篇 |
1979年 | 1684篇 |
1978年 | 1309篇 |
1977年 | 1002篇 |
1976年 | 1123篇 |
1975年 | 791篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Elizabeth D. Krebs Robert B. Hawkins J. Hunter Mehaffey Clifford E. Fonner Alan M. Speir Mohammed A. Quader Jeffrey B. Rich Leora T. Yarboro Nicholas R. Teman Gorav Ailawadi 《The Journal of thoracic and cardiovascular surgery》2019,157(4):1533-1542.e2
Objectives
Expedient extubation after cardiac surgery has been associated with improved outcomes, leading to postoperative extubation frequently during overnight hours. However, recent evidence in a mixed medical-surgical intensive care unit population demonstrated worse outcomes with overnight extubation. This study investigated the impact of overnight extubation in a statewide, multicenter Society of Thoracic Surgeons database.Methods
Records from 39,812 patients undergoing coronary artery bypass grafting or valve operations (2008-2016) and extubated within 24 hours were stratified according to extubation time between 06:00 and 18:00 (day) or between 18:00 and 6:00 (overnight). Outcomes including reintubation, mortality, and composite morbidity-mortality were evaluated using hierarchical regression models adjusted for Society of Thoracic Surgeons predictive risk scores. To further analyze extubation during the night, a subanalysis stratified patients into 3 groups: 06:00 to 18:00, 18:00 to 24:00, and 24:00 to 06:00.Results
A total of 20,758 patients were extubated overnight (52.1%) and were slightly older (median age 66 vs 65 years, P < .001) with a longer duration of ventilation (4 vs 7 hours, P < .001). Day and overnight extubation were associated with equivalent operative mortality (1.7% vs 1.7%, P = .880), reintubation (3.7% vs 3.4%, P = .141), and composite morbidity-mortality (8.2% vs 8.0%, P = .314). After risk adjustment, overnight extubation was not associated with any difference in reintubation, mortality, or composite morbidity-mortality. On subanalysis, those extubated between 24:00 and 06:00 exhibited increased composite morbidity-mortality (odds ratio, 1.18; P = .001) but no difference in reintubation or mortality.Conclusions
Extubation overnight was not associated with increased mortality or reintubation. These results suggest that in the appropriate clinical setting, it is safe to routinely extubate cardiac surgery patients overnight. 相似文献12.
13.
14.
15.
16.
目的探讨改良内固定融合术治疗成人Ⅱ型痛性足副舟骨(painful accessory navicular,PAN)的疗效。方法2016 年 1 月—2017 年 12 月,采用改良内固定融合术治疗 29 例(37 足)Ⅱ型 PAN。其中男 12 例,女 17 例;年龄 18~50 岁,平均 41.4 岁。扭伤 24 例,无明显诱因 5 例。患者均行 6 个月以上保守治疗,症状无明显改善。术前及末次随访时采用美国矫形足踝协会(AOFAS)中足评分评估临床疗效;X 线片测量跟骨倾斜角、距骨第 1 跖骨角、距舟关节包容角、距骨第 2 跖骨角。结果术后 1 例出现切口浅表感染,经加强换药后愈合;其余患者切口均Ⅰ期愈合,无深部感染或骨髓炎发生。29 例均获随访,随访时间 12~33 个月,平均 25.1 个月。X 线片示关节面均于术后 2~5 个月愈合,平均 3.4 个月。随访期间未见内固定物松动或断裂。末次随访时,AOFAS 疼痛、功能、力线评分及总分以及距舟关节包容角、距骨第 1 跖骨角和距骨第 2 跖骨角均较术前显著改善,差异有统计学意义(P<0.05);跟骨倾斜角手术前后差异无统计学意义(t=1.097,P=0.276)。 结论采用改良内固定融合术治疗成人Ⅱ型 PAN 可有效缓解症状,患足功能恢复良好,并发症少。 相似文献
17.
18.
《Vaccine》2020,38(3):570-577
IntroductionPediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs).MethodsIn a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped.ResultsS. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1–4.3 years] vs. median 5.6 years [IQR 3.8–8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1.ConclusionFollowing the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3. 相似文献
19.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
20.